Allurion Technologies (OTCID: ALUR) appeals NYSE delisting and leans on new FDA approval
Rhea-AI Filing Summary
Allurion Technologies received notice that the New York Stock Exchange will begin proceedings to delist its common stock and warrants after the company failed to meet the NYSE rule requiring an average global market capitalization of at least
The company recently obtained U.S. FDA approval for its Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, and has presented the NYSE with a multi-step plan to regain compliance or qualify for listing on NYSE American, strengthen its balance sheet, and fund U.S. commercialization of the Smart Capsule. Management cautions there is no assurance the appeal or relisting efforts will succeed, and notes that liquidity, trading volume and broker quoting on the OTC market may be limited.
Positive
- Recent FDA approval provides growth catalyst: The company obtained U.S. FDA approval for the Allurion Gastric Balloon System featuring the Allurion Smart Capsule on February 20, 2026, and is using this as the foundation of a detailed plan to strengthen its balance sheet and fund U.S. commercialization.
Negative
- NYSE initiates delisting due to low market cap: The NYSE determined to delist Allurion’s common stock and warrants after the company failed to maintain the required average global market capitalization of at least
$15,000,000 over 30 consecutive trading days, leading to suspension of NYSE trading and migration to the OTCID Market.
Insights
NYSE delisting move is clearly negative despite an active remediation plan.
Allurion Technologies has fallen below the NYSE’s continued listing requirement for an average global market capitalization of at least
The shares now trade on the OTCID Market, which typically entails lower liquidity, wider spreads and reduced institutional participation compared with a major exchange. The company has appealed and is executing a plan, tied partly to recent FDA approval of the Allurion Gastric Balloon System, to regain NYSE compliance or relist on NYSE American and bolster its balance sheet.
Outcome uncertainty remains high because the appeal may fail and there is no assurance the securities will continue trading on OTCID with sufficient volume. The delisting risk, combined with potential reputation and volatility effects, makes this development materially adverse from a capital markets and financing perspective, even as FDA approval offers longer-term commercial potential.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On March 6, 2026, the New York Stock Exchange (“NYSE”) notified Allurion Technologies, Inc. (“Allurion” or the “Company”) that it has determined to commence proceedings to delist the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and warrants to purchase 0.056818 shares of Common Stock, with an exercise price of $202.50 per share of Common Stock (the “Warrants”), as a result of the Company’s non-compliance with Rule 802.01B of the NYSE Listed Company Manual that requires listing companies to maintain an average global market capitalization of at least $15 million over a period of 30 consecutive trading days. Trading in the Common Stock on the NYSE was suspended after market close on March 6, 2026. The Company has appealed this delisting determination. If the Company is unsuccessful in its appeal, the Company expects the NYSE will file a Form 25 with the Securities and Exchange (the “SEC”), which would result in the delisting of the Company’s Common Stock and Warrants from the NYSE on the tenth day after the Form 25 is filed.
As a result of the suspension in trading and delisting process pending the Company’s appeal, the Common Stock is trading on the OTCID Market (the “OTCID Market”). The Company intends to apply to list on a higher-tier market operated by the OTC Market Group, Inc. under its current symbols "ALUR" and “ALUR.WS”.
The Company can provide no assurance that the Common Stock or Warrants will continue to trade on this market, whether broker-dealers will continue to provide public quotes of the Common Stock and Warrants on this market, or whether the trading volume of the Common Stock and Warrants will be sufficient to provide for an efficient trading market for existing and potential holders of the Common Stock and Warrants.
The transition to the OTCID Market is not expected to affect the Company’s business operations or its current SEC reporting obligations.
Item 8.01 Other Events.
On March 12, 2026, the Company issued a press release in connection with the delisting notice of its Common Stock and Warrants from the NYSE and its appeal of the delisting determination described above.
As discussed in the press release, the Company's recent FDA approval of the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, catalyzed a detailed plan to regain compliance with NYSE listing standards or to relist its securities on the NYSE American, strengthen its balance sheet, and fund commercialization of the Allurion Smart Capsule in the U.S. This plan has been shared with the NYSE and is currently being executed by the Company's management.
The press release is filed as Exhibit 99.1 and is hereby incorporated by reference herein.
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding the Company’s appeal of the delisting determination and the potential success of such appeal; the potential delisting of the Company following the filing of the Form 25; its expectations regarding trading on the OTCID Market; its plan to strengthen its balance sheet and fund commercialization of the Allurion Smart Capsule in the U.S.; and its intention to regain compliance with NYSE’s continued listing standards or another stock exchange’s initial listing standards. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of the Company’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of the Company to maintain regulatory approvals for and successfully commercialize its products and offerings, including the Allurion Balloon, (ii) the timing of, and results from, the Company’s clinical studies and trials, (iii) the evolution of the markets in which the Company competes, (iv) the ability of the Company to defend its intellectual property and satisfy regulatory requirements, (v) the impact of global economic conditions and geopolitical events on the Company’s business, (vi) the Company’s expectations regarding its market opportunities, (vii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which the Company operates, (viii) the risk that the Delisting Notice and noncompliance with NYSE continued listing standards may impact the Company’s results of operations, business operations and reputation and the trading prices and volatility of the Company’s common stock, (ix) the Company’s ability to regain compliance with NYSE continued listing standards or to satisfy the initial listing standards of another nationally recognized securities exchange. The foregoing list of factors is not exhaustive and (x) the Company’s ability to complete a transaction or transactions to achieve compliance with the Exchange’s requirements on acceptable terms, or at all. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed on March 27, 2025, and as amended on August 19, 2025, and updated from time to time by its other filings with the SEC, and its Quarterly Report on Form 10-Q filed with the SEC on November 17, 2025. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Allurion undertakes no obligation to
update any forward-looking statements to reflect any new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events, other than as required by applicable law.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
|
Exhibit |
|
Description |
99.1 |
|
Press Release dated March 12, 2026. |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Allurion Technologies, Inc. |
|
|
|
|
Date: |
March 12, 2026 |
By: |
/s/ Brendan M. Gibbons |
|
|
Name: Title: |
Brendan M. Gibbons |
Exhibit 99.1
Allurion Advances Plan to Regain Listing Compliance
Files appeal to NYSE on decision to initiate delisting proceedings
Company’s recent FDA approval catalyzes plan to regain compliance with the continued listing requirements of NYSE or initial listing requirements of the NYSE American
NATICK, Mass. – March 12, 2026 – Allurion Technologies, Inc. (the “Company”) (OTCID: ALUR), a pioneer in metabolically healthy weight loss, announced today that it has appealed the decision by the New York Stock Exchange (the “NYSE”) to initiate delisting proceedings against Allurion’s securities pursuant to Section 802.01B of the NYSE’s Listed Company Manual, which requires listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000.
The Company’s recent FDA approval of the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, catalyzed a detailed plan to regain compliance with NYSE listing standards or to relist its securities on the NYSE American, strengthen its balance sheet, and fund commercialization of the Allurion Smart Capsule in the U.S. This plan has been shared with the NYSE and is currently being executed by the Company’s management.
“We have been in regular contact with the NYSE about our step-by-step plan to regain compliance with its listing standards or initiate listing on the NYSE American,” said Dr. Shantanu Gaur, Founder and Chief Executive Officer. “The first step in our plan was receiving FDA approval, which was received on February 20, 2026. We are leveraging this approval to touch off the remaining parts of our plan to ultimately regain compliance or relist.
“We are confident we can execute this plan, setting up Allurion to capitalize on our U.S. FDA approval and enabling us to treat the more than 100 million Americans suffering from obesity, 20 million of whom have already tried a GLP-1 but discontinued use,” Dr. Gaur concluded.
While the Company has appealed the NYSE’s decision and is working diligently to regain compliance with the NYSE or relist on the NYSEA, there can be no assurance that these efforts will be successful. The Company’s securities are trading on the OTCID exchange while the Company works to execute its above-referenced plan.
Forward-Looking Statements
This press release contains forward-looking statements that reflect Allurion’s beliefs and assumptions based on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terms, although not all forward-looking statements contain these words. Although Allurion believes it has a reasonable basis for each forward-looking statement contained in this release, these statements involve risks and uncertainties that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.
Forward-looking statements in this press release include, but are not limited to, statements regarding: our efforts to to regain compliance with NYSE listing standards or to relist its securities on the NYSE American, strengthen our balance sheet, and fund commercialization of the Allurion Smart Capsule in the U.S.; establishing a new standard for weight loss; pioneering in metabolically healthy weight loss; and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to management.
Allurion cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward looking statements are subject to a number of risks and uncertainties, including, among others, general economic, political and business conditions; the ability of Allurion to obtain and maintain regulatory approval for, and successfully commercialize, the Allurion Gastric Balloon System, including the Allurion Smart
Capsule; the timing of, and results from, Allurion’s clinical studies and trials, including with respect to the combination of GLP-1s with the Allurion Smart Capsule; the evolution of the markets in which Allurion competes, including the impact of GLP-1 drugs; the ability of Allurion to regain compliance with the continued listing standards of the New York Stock Exchange or qualify for an initial listing on another exchange; a changing regulatory landscape in the highly competitive industry in which Allurion competes; the impact of the imposition of current and potential tariffs and trade negotiations, and those factors discussed under the heading “Risk Factors” in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 27, 2025, and as amended on August 19, 2025, and updated from time to time by its other filings with the SEC, and its Quarterly Report on Form 10-Q filed with the SEC on November 17, 2025. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Allurion undertakes no obligation to update any forward-looking statements to reflect any new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events, other than as required by applicable law.
Investor Contact
investors@allurion.com
FAQ
Why is Allurion Technologies (ALUR) facing NYSE delisting?
Where are Allurion Technologies (ALUR) shares trading after NYSE suspension?
How is Allurion responding to the NYSE delisting notice?
What recent FDA approval did Allurion Technologies receive?
Will the NYSE delisting affect Allurion’s business operations or SEC reporting?
What risks does Allurion highlight regarding its appeal and relisting plans?
Filing Exhibits & Attachments
2 documentsPress Releases
